secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apimeds Pharmaceuticals US, Inc. (APUS)
CIK:        0001894525
Form:       8-K
Filed at:   2025-12-02T23:59:59+00:00
Accession:  0001213900-25-117173
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 1.01, 2.01, 2.03, 3.02, 5.01, 5.02, 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Apimeds Pharmaceuticals US completes merger with MindWave Innovations, issues 90.9% equity to MindWave holders
--------------------------------------------------------------------------------

- On Dec 1, 2025, Apimeds (APUS) merged with MindWave Innovations, with MindWave surviving as wholly owned subsidiary.
- MindWave stockholders received 29.9% of Apimeds common stock and 61% convertible preferred (as-converted), totaling 90.9% of post-merger equity.
- Apimeds entered a $120.9M convertible note financing with 8% OID, issuing senior convertible notes.
- CEO Erik Emerson resigned, replaced by Dr. Vin Menon; two new directors appointed.
- Apimeds will effect a 1-for-10 reverse stock split and increase equity plan shares to 2,096,679.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1894525/000121390025117173/0001213900-25-117173-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1894525/000121390025117173/ea0267807-8k425_apimeds.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-117173

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer